| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
Form 4: Savage William Jacob, Chief Medical Officer
Sold 16,035 shares ($1.36M) |
| 10 Nov 2026 | 144 |
| 05 Nov 2026 | 424B5 |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints |
| 26 Oct 2026 | SCHEDULE 13D/A |
| 22 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
Disc Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) 6,000,000 shares of its common stock, par value $0.0001 per share (the “F... |
| 21 Oct 2026 |
Form 4: Bitterman Kevin, Director
Sold 10,994 shares ($879K) · Sold 5,312 shares ($425K) · Sold 25,519 shares ($2.05M) |
| 21 Oct 2026 | 424B5 |
| 21 Oct 2026 | 144 |
| 21 Oct 2026 | 144 |
| 21 Oct 2026 | 144 |
| 21 Oct 2026 | 144 |
| 20 Oct 2026 | 144 |
| 20 Oct 2026 | 144 |
| 20 Oct 2026 | 144 |
| 20 Oct 2026 | 144 |
| 20 Oct 2026 | 424B5 |
| 19 Oct 2026 | 144 |
| 19 Oct 2026 | 144 |
Loading...